What is the recommended treatment for an adult with acute pulmonary embolism, including anticoagulation, thrombolytic therapy, and alternatives for contraindications?

Treatment of Pulmonary Embolism

Initiate anticoagulation immediately without delay in all patients with suspected PE while diagnostic workup proceeds, using NOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) as first-line therapy over warfarin for most patients, with treatment stratified by hemodynamic risk. 1

Risk-Stratified Treatment Approach

High-Risk PE (Hemodynamic Instability/Shock)

For patients with hypotension or shock:

• Immediate unfractionated heparin (UFH) with weight-adjusted bolus injection 1
• Systemic thrombolytic therapy is mandatory (Class I, Level B recommendation) 1
• If thrombolysis contraindicated or fails: Surgical pulmonary embolectomy (Class I recommendation) 1
• Alternative to surgery: Percutaneous catheter-directed treatment when thrombolysis contraindicated/failed 1
• Hemodynamic support: Norepinephrine and/or dobutamine 1
• ECMO consideration: For refractory circulatory collapse or cardiac arrest, combined with surgical embolectomy or catheter-directed treatment 1

The 2019 ESC guidelines establish clear hierarchy: thrombolysis first, surgery when thrombolysis cannot be used, and catheter-directed therapy as an alternative to surgery in specialized centers 1.

Intermediate- or Low-Risk PE (Hemodynamically Stable)

Anticoagulation strategy:

• Start anticoagulation immediately even before diagnostic confirmation if clinical probability is high or intermediate 1
• Preferred parenteral agents: LMWH or fondaparinux over UFH (Class I, Level A) 1
• Preferred oral anticoagulation: NOACs over vitamin K antagonists (VKAs) (Class I, Level A) 1
• If using VKA: Overlap with parenteral anticoagulation until INR 2.5 (range 2.0-3.0) achieved 1

Thrombolysis in stable patients:

• Routine systemic thrombolysis is NOT recommended in intermediate- or low-risk PE (Class III, Level B) 1, 2
• Rescue thrombolytic therapy IS recommended if hemodynamic deterioration occurs on anticoagulation (Class I, Level B) 1
• The 2021 CHEST guidelines confirm thrombolysis reduces recurrent PE and mortality in high-risk patients but increases major bleeding (65 more events per 1,000 cases), with benefits and harms finely balanced in intermediate-risk patients 2

Critical Contraindications and Special Populations

NOACs are contraindicated in:

• Severe renal impairment 1
• Pregnancy and lactation 1
• Antiphospholipid antibody syndrome 1

For these patients: Use LMWH/fondaparinux bridged to warfarin with INR monitoring.

Inferior Vena Cava Filters

IVC filters should be considered (Class IIa) in:

• Acute PE with absolute contraindications to anticoagulation 1, 2
• PE recurrence despite therapeutic anticoagulation 1

Routine IVC filter use is NOT recommended (Class III, Level A) 1. The 2021 CHEST guidelines strongly recommend against IVC filters in addition to anticoagulation for acute DVT, as they increase mortality and recurrent PE at 90 days 2.

Catheter-Directed vs. Systemic Thrombolysis

When thrombolysis is indicated, systemic thrombolytic therapy via peripheral vein is preferred over catheter-directed thrombolysis (weak recommendation) 2. However, catheter-assisted thrombus removal should be considered in high-risk PE patients with:

• High bleeding risk
• Failed systemic thrombolysis
• Shock likely to cause death before systemic thrombolysis takes effect 2

Recent 2025 data suggests alteplase has lower major bleeding rates (10.9%) compared to tenecteplase (31.1%) and ultrasound-assisted CDT (21.4%), though disease severity varied between groups 3.

Multidisciplinary PE Response Teams (PERTs)

Establish PERT consultation for high-risk and selected intermediate-risk PE cases 1. These teams facilitate real-time decision-making for complex cases requiring advanced interventions, bringing together cardiology, pulmonology, interventional radiology, cardiac surgery, and intensive care specialists.

Early Discharge Considerations

Carefully selected low-risk PE patients should be considered for early discharge with home treatment continuation if proper outpatient care and anticoagulation can be provided (Class IIa, Level A) 1.

Common Pitfalls to Avoid

• Do not delay anticoagulation waiting for diagnostic confirmation in high-probability patients
• Do not use routine thrombolysis in hemodynamically stable patients—bleeding risk outweighs benefit
• Do not use NOACs in severe renal impairment, pregnancy, or antiphospholipid syndrome
• Do not place IVC filters routinely—reserve for absolute anticoagulation contraindications
• Do not use UFH when LMWH/fondaparinux available for intermediate/low-risk PE